...
首页> 外文期刊>The journal of immunology >Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells
【24h】

Induction of Antigen-Specific CTL by Recombinant HIV Trans-Activating Fusion Protein-Pulsed Human Monocyte-Derived Dendritic Cells

机译:重组HIV反式激活融合蛋白脉冲人单核细胞衍生的树突状细胞诱导抗原特异性CTL。

获取原文
           

摘要

Several systems have been tested for introduction of Ags into human dendritic cells (DC). Most of them to date, however, are complex and possess limited efficiency. Recent advances in HIV trans -activating (TAT) fusion protein technology permit extremely high transduction efficiencies for a majority of mammalian cell types. Here we report our attempts to develop a simple, but highly efficient, protocol for loading of antigenic protein into DC using TAT fusion technology. A TAT-minigene fusion protein was generated, encoding both the HLA-A2-restricted influenza matrix protein-derived epitope (GILVFTFTL, Flu-M1) and a melanoma Ag gp100-derived modified epitope (YLEPGPVTV, G9280-9V). In addition, both a TAT-Her2eu extracellular domain (ECD) fusion protein and a TAT-green fluorescence protein fusion protein were generated. Over 95% of DC stained positively for TAT-green fluorescence protein within 20 min of coculture. DC treated with TAT-minigene were efficiently recognized by both Flu-M1 and G9280-9V-specific T cells in cytotoxicity assays and IFN-γ ELISPOT assays. In contrast, DC pulsed with minigene fusion protein lacking TAT were either poorly recognized or not recognized by the T cells. DC pulsed with TAT-minigene also efficiently induced Flu-M1-specific T cells from naive lymphocytes. Similarly, DC treated with TAT-Her2eu ECD stimulated patient-derived lymphocytes that specifically recognized Her2eu+ ovarian and breast cancer cell lines. The CTL induced by TAT-Her2eu ECD-pulsed DC specifically recognized the Her2eu ECD-derived immunogenic peptide E75 (KIFGSLAFL). Our data suggest that TAT fusion proteins efficiently transduce DC and induce Ag-specific T cells. This could prove to be a useful method for treatment of infectious diseases and cancer.
机译:已测试了几种将Ags引入人树突状细胞(DC)的系统。但是,迄今为止,它们大多数都是复杂的,效率有限。 HIV反式激活(TAT)融合蛋白技术的最新进展为大多数哺乳动物细胞类型提供了极高的转导效率。在这里,我们报告了我们的尝试,以开发一种简单但高效的协议,使用TAT融合技术将抗原蛋白加载到DC中。生成了TAT-minigene融合蛋白,编码HLA-A2限制性流感病毒基质蛋白衍生的抗原决定簇(GILVFTFTL,Flu-M1)和黑素瘤Ag gp100衍生的修饰抗原决定簇(YLEPGPVTV,G9280-9V)。另外,产生了TAT-Her2 / neu胞外域(ECD)融合蛋白和TAT-绿色荧光蛋白融合蛋白。共培养20分钟内,超过95%的DC对TAT-绿色荧光蛋白呈阳性染色。在细胞毒性试验和IFN-γELISPOT试验中,Flu-M1和G9280-9V特异性T细胞均有效识别了用TAT-minigene处理的DC。相反,用TTA的小基因融合蛋白脉冲的DC被T细胞识别不佳或未被识别。用TAT-minigene脉冲的DC还可以有效地从幼稚淋巴细胞诱导出Flu-M1特异性T细胞。同样,用TAT-Her2 / neu ECD处理的DC刺激了患者来源的淋巴细胞,这些淋巴细胞特异性识别了Her2 / neu +卵巢癌和乳腺癌细胞系。由TAT-Her2 / neu ECD脉冲DC诱导的CTL特异性识别Her2 / neu ECD衍生的免疫原性肽E75(KIFGSLAFL)。我们的数据表明,TAT融合蛋白可以有效地转导DC并诱导Ag特异性T细胞。这可能被证明是治疗传染病和癌症的有用方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号